ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!Avadel Pharmaceuticals plc (AVDL) stock declined over -2.18%, trading at $7.84 on NASDAQ, down from the previous close of $8.01. The stock opened at $7.99, fluctuating between $7.76 and $8.04 in the recent session.
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Employees | 188 |
Beta | 1.57 |
Sales or Revenue | $27.96M |
5Y Sales Change% | -0.874% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com